NextCell Pharma AB (FRA:65G)

NextCell Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is September - August.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Net Income	-35.14	-41.96	-39.81	-34.55	-24.56
Depreciation & Amortization	2.52	0.97	0.45	0.46	0.44
Loss (Gain) From Sale of Assets	-	-	-	0.14	-
Other Operating Activities	-	-0	-	-	-
Change in Accounts Receivable	-1.79	3.17	-7.59	-1.56	-3.24
Change in Inventory	-	0.25	-0.02	-0.77	-
Change in Accounts Payable	-3.47	5.26	-1.03	0.64	0.98
Change in Other Net Operating Assets	-0.98	-5.47	4.18	2.33	0.8
Operating Cash Flow	-38.86	-37.78	-43.83	-33.31	-25.58
Capital Expenditures	-4.18	-0.08	-4.1	-7.59	-0.73
Investment in Securities	-0.06	-0	-0	-1.76	-5.11
Other Investing Activities	-0	-	-	-	-
Investing Cash Flow	-4.24	-0.08	-4.1	-9.35	-5.84
Long-Term Debt Issued	1.1	0.8	0.84	0.61	0.2
Net Debt Issued (Repaid)	1.1	0.8	0.84	0.61	0.2
Issuance of Common Stock	36.56	40.09	-	-	164.72
Other Financing Activities	-2.63	-6.25	-	-	-16.29
Financing Cash Flow	35.03	34.63	0.84	0.61	148.63
Miscellaneous Cash Flow Adjustments	0	-	-	-	-
Net Cash Flow	-8.07	-3.23	-47.09	-42.05	117.21
Free Cash Flow	-43.05	-37.86	-47.92	-40.9	-26.3
Free Cash Flow Margin	-389.04%	-335.70%	-343.41%	-656.63%	-590.41%
Free Cash Flow Per Share	-0.56	-0.93	-1.39	-1.19	-0.86
Cash Interest Paid	0	0	0	0.01	0.01
Levered Free Cash Flow	-30.33	-22.93	-33.74	-28.38	-17.26
Unlevered Free Cash Flow	-30.33	-22.93	-33.74	-28.37	-17.26
Change in Working Capital	-6.24	3.21	-4.46	0.65	-1.46

Source: S&P Global Market Intelligence. Standard template. Financial Sources.